100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Salt Composition in bothRepaglinide 1mg + Voglibose 0.3mg
You Searched
Our Recommendation
Rapiglinide Vog 1/0.3mg Tablet 15s
Steris Healthcare Pvt. Ltd.
504+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
Used In
Treatment of Type 2 diabetes mellitus
Customers also bought
More About Voglizar R 1mg/0.3mg Tablet
Benefits
In Treatment of Type 2 diabetes mellitus Voglizar R 1mg/0.3mg Tablet is a medicine that helps to control high blood glucose (sugar) levels. It helps get rid of extra glucose from your body through urine. It helps to slow down the breaking down of food in our intestine to simple glucose (sugar), thereby decreasing the rise in blood glucose levels after meals. Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level, you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems and loss of limbs. Voglizar R 1mg/0.3mg Tablet will reduce the risk of dying from cardiovascular disease if you have type 2 diabetes and already have cardiovascular disease. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed because it is protecting your future health.
Side Effects
The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you're worried about them.
How to use
Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Voglizar R 1mg/0.3mg Tablet is to be taken with food.
How it works
Voglizar R 1mg/0.3mg Tablet is a combination of two antidiabetic medicines: Repaglinide and voglibose. Repaglinide is a meglitinide analogue which increases the amount of insulin released by the pancreas. Voglibose is an alpha-glucosidase inhibitor which inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose. Together, they prevent blood sugar from rising very high after meals.
Unsafe: Avoid consuming alcohol with Voglizar R 1mg/0.3mg Tablet as it is deemed unsafe.
Seek medical advice from your doctor: Voglizar R 1mg/0.3mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Seek medical advice from your doctor: Voglizar R 1mg/0.3mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Caution Advised: Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Caution Advised: Voglizar R 1mg/0.3mg Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Voglizar R 1mg/0.3mg Tablet may be needed. Doctor consultation is advised.
Caution Advised: Voglizar R 1mg/0.3mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Voglizar R 1mg/0.3mg Tablet may be needed. Doctor consultation is advised.
What if I forget to take it?
If a dose of Voglizar R 1mg/0.3mg Tablet is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Manufacturer Address
F-11, F-12, F-13, 1st FLOOR, NARAYAN KRUPA COMPLEX NEAR LALGEBI ASHRAM, GHUMA AHMEDABAD GJ 380058 IN , - , .
References
Repaglinide. Gatwick, West Sussex: Novo Nordisk Limited; 2001 (29 Apr. 2019)
Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An Alpha Glucosidase Inhibitor. J Clin Diagn Res. 2013;7(12):3023-7 (12 Mar. 2019)
Repaglinide and Voglibose Tablets (28 October 2021)
Repaglinide and Voglibose Tablets (28th Sept. 2023)
Disclaimer
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
